Needham likes Geron in premarket analyst action

  • Ionis Pharmaceuticals (NASDAQ:IONS) initiated with Neutral rating at Cantor Fitzgerald citing Spinraza headwinds.
  • Cerecor (NASDAQ:CERC) initiated with Buy rating and $10 (93% upside) price target at Maxim Group. Shares up 2% premarket.
  • BioMarin Pharmaceutical (NASDAQ:BMRN) resumed with Outperform rating and $110 (19% upside) price target at Raymond James.
  • Geron (NASDAQ:GERN) upgraded to Buy with a $3 (63% upside) price target at Needham. Shares up 4% premarket.
  • PerkinElmer (NYSE:PKI) upgraded to Buy with a $115 (15% upside) price target at Goldman Sachs.
  • Zogenix (NASDAQ:ZGNX) downgraded to Neutral with a $40 (23% downside risk) price target at Guggenheim after the FDA rejected its incomplete Fintepla application. Shares down 31% premarket.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.